Efficacy of Therapeutic Plasma Exchange Alone or in Combination with Ruxolitinib for the Treatment of Penn Class 3 and 4 Cytokine Release Syndrome Complicating COVID-19 Article Swipe

PDF

Related Concepts

Cytokine release syndrome Coronavirus disease 2019 (COVID-19) Cytokine Medicine Ruxolitinib Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Therapeutic plasma exchange 2019-20 coronavirus outbreak Pharmacology Internal medicine Virology Bone marrow Disease Outbreak Infectious disease (medical specialty) Myelofibrosis

William Larry Gluck , Wesley Smith , Sean Callahan , Robert Brevetta , Antine E. Stenbit , Julie Martin , Anna V. Blenda , Sergio Arce , William J. Edenfield ·

YOU? · · 2021 · Open Access · · DOI: https://doi.org/10.33696/immunology.3.100 · OA: W3195324142

This study was conducted to validate the efficacy of therapeutic plasma exchange (TPE) in reducing the excessive cytokine load complicating a subset of patients with severe COVID-19 and respiratory compromise. Additionally, this trial explored molecular signals of potential benefit by the addition of JAK inhibition to TPE